Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.52 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.52 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CPN1 | P15169 | 2/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940615 | 1.00 | SLC6A1 (0.52) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL29499900 | 1.00 | SLC6A1 (0.52) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL29642926 | 0.98 | SLC6A1 (0.50) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL30484345 | 0.98 | SLC6A1 (0.50) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL488818 | 0.88 | — | — | |
| SCHEMBL488817 | 0.88 | — | — | |
| SCHEMBL488899 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL30595524 | 0.86 | SLC6A1 (0.64) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL28195837 | 0.86 | SLC6A1 (0.64) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL3207142 | 0.84 | EPHX1 (0.54) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | claimed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | claimed |
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023213269-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2023-11-09 | — | — | WO | disclosed |
| EP-4001888-B1 | BIOLOGICAL TISSUE STAINING REAGENT, BIOLOGICAL TISSUE STAINING KIT AND BIOLOGICAL TISSUE STAINING METHOD | CUBICSTARS INC (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
| EP-0888351-B1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | THOMAE GMBH DR K (DE) | 2003-10-15 | — | — | EP | disclosed |
| CN-1064362-C | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 2001-04-11 | — | — | CN | disclosed |
| CN-1212694-A | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | disclosed |
| EP-0888351-A1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-01-07 | — | — | EP | disclosed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | disclosed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | SLC6A1 4577/4885SLC6A11 4811/4885SLC6A13 4835/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | SLC6A1 209/4885SLC6A11 252/4885SLC6A13 389/4885 |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | SLC6A1 1208/4885SLC6A11 1392/4885SLC6A13 2691/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | SLC6A1 209/4885SLC6A11 252/4885SLC6A13 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.